A nonfatal case and 2 fatal cases of paraneoplastic pemphigus: Can a complement indirect immunofluorescent test help to identify fatal "group A" paraneoplastic pemphigus cases?

Journal of the American Academy of Dermatology

Volumn 47, Issue 6, 2002, Pages 841-851

  Beutner, Ernst H ^a,g   Pelton, Stephen ^b   Hashimoto, Takashi ^c   Xu, Yuelin ^d   Plunkett, Richard W ^a   Korman, Neil J ^e   Helm, Thomas N ^a   Jablonska, Stefania ^f  

^a UNIVERSITY AT BUFFALO   (United States)

^b Barrington Park Dermatology   (United States)

^c KEIO UNIVERSITY   (Japan)

^d GG Messenger MD   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g Beutner Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBODY; COBALT 60; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ANALYSIS; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER SURGERY; CASE REPORT; CELL SURFACE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COBALT THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESMOSOME; DISEASE CLASSIFICATION; DISEASE COURSE; ESOPHAGUS; FATALITY; HUMAN; IMMUNOFLUORESCENCE; LYMPHOMA; MALE; MONKEY; PARANEOPLASTIC SYNDROME; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; SERUM; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TISSUE SECTION; TREATMENT OUTCOME;

EID: 0036895354     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.123486     Document Type: Article

References (40)

1. Anhalt GJ, Kim S, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990;323:1729-35.
2. Lever WF. Pemphigus and Pemphigoid. Springfield (IL): Charles C. Thomas; 1965. p. 1-266.
3. Beutner EH, Lever WF, Witebsky E, Jordon RE, Chertock B. Auto-antibodies in pemphigus vulgaris. Responses to an intercellular substance of epidermis. JAMA 1965;192:682-8.
4. Beutner EH, Jordon RE, Chorzelski TP. The immunopathology of pemphigus and bullous pemphigoid. J Invest Dermatol 1968;51:63-80.
5. Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 2000;43:619-26.
6. Helm TN, Beutner EH, Kulick KB, Korman NJ, Plunkett RW. Complement fixing immunofluorescence findings may correlate with clinical outcome in patients with paraneoplastic pemphigus. J Am Acad Dermatol In press.
7. Hashimoto T, Amagai M, Wantanabe K, Chorzelski TP, Bhogal BS, Black MM, et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 1995;104:829-34.
8. Camisa C, Helm TN, Liu YC, Valenzuela R, Allen C, Bona S, et al. Paraneoplastic pemphigus: A report of three cases including one long-term survivor. J Am Acad Dermatol 1992;27:547-53.
9. Camisa C, Helm TN. Paraneoplastic pemphigus is a distant neoplasia-induced autoimmune disease. Arch Dermatol 1993;129:883-6.
10. Sklavounou A, Laskaris G. Paraneoplastic pemphigus: A review. Oral Oncol 1998;35:437-40.
11. Joly P, Thomine E, Gilbert D, Verdier S, Delpech A, Prost C, et al. Overlapping distribution of autoantibody specificities in paraneo-plastic pemphigus and pemphigus vulgaris. J Invest Dermatol 1994;103:65-72.
12. Chiewchanvit S, Hashimoto T, Chaiwun B, Nashikawa T. A pemphigus case with long term survival, implicating the spectrum between paraneoplastic pemphigus and pemphigus vulgaris. Int J Dermatol 1997;36:957-8.
13. Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T. Antigen specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 1995,104:895-901.
14. Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 1998;102:775-82.
15. Beutner EH, Sepulveda MR, Barnett EV. Quantitative studies of immunofluorescent staining. II. Relationships of characteristics of unabsorbed antihuman IgG conjugates to their specific and non-specific staining properties in an indirect test for antinuclear factors. WHO Bull 1968;39:587-606.
16. Beutner EH. Field trials by ten laboratories of six commercial conjugates prepared from antisera to human IgG. Ann NY Acad Sci 1971;177:361-403.
17. Beutner EH. Defined immunofluorescent staining: Past progress, present status and future prospects for defined conjugates. Ann N Y Acad Sci 1971;177:506-26.
18. Beutner EH, Binder WL, Fang YV, Plunkett RW, Rubin RL. Antinuclear antibodies (ANA) and complement fixing ANA in systemic connective tissue diseases. Immunol Invest 1998;27:97-104.
19. Stanley JR, Yaar M, Hawley Nelson P, Katz SI. Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. J Clin Invest 1982;70:194-6.
20. Chorzelski TP, Hashimoto T, Maciejewska B, Amagai M, Anhalt GJ, Jablonska S. Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis, and bronchiolitis obliterans. J Am Acad Dermatol 1999;41:393-400.
21. Musialowicz D, Hashimoto T, Jarzabek-Chorzelska M, Szczesniak N, Kolacinska-Strasz, Jablonska S. [Paraneoplastic pemphigus associated with spindel cell sarcoma. Coexistence of antibodies against plakins and desmogleins]. Przegl Dermatol 2000;89:139-46. Polish.
22. Llanos M, Taberno J, Brunet J, Amendo M, Pallares C, de Andres L, et al. CHOP chemotherapy of intermediate and high-grade non-Hodgkin's lymphoma. Acta Oncol 1994;33:935-9.
23. Miller TP. Management of intermediate-grade lymphomas. Oncology (Huntingt) 1998;12(Suppl 8):35-9.
24. Santoro A, Balzarotti M, Tondini C, Zanini M, Giardini R, Latteri F, et al. Dose-escalation of CHOP in non-Hodgkin's lymphoma. Ann Oncol 1999;10:519-25.
25. Becker LR, Bastian BC, Wesselmann U, Karl S, Hamm H, Brocker EB. Paraneoplastic pemphigus treated with dexamethasone/cyclophosphamide pulse therapy. Eur J Dermatol 1998;8:551-3.
26. Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol 1999;40:750-4.
27. Soussain C, Souleau B, Gabarre J,Zouabe H, Sutton L, Boccaccio C, et al. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients. Leuk Lymphoma 1999;33:543-50.
28. Petit J, Boque C, Cancelas JA, Sarra J, Munoz J, Garcia J, et al. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilization regimen in resistant and relapsed lymphoma: A single-center study of 22 patients. Leuk Lymphoma 1999;34:119-27.
29. Hellmann S, Grint P. Important Drug Warning: Updated Safety Information. Genentech Inc, IDEC Pharmaceuticals Corp; May 8, 2001.
30. Klein G, Steiner M, Weiner F, Klein E. Human leukemia-associated antinuclear reactivity. Proc Nat Acad Sci U S A 1974;71:685-9.
31. Tojo T, Friou JG. Lupus nephritis: Varying complement-fixing properties of immunoglobulins G antibodies to antigens of cell nuclei. Science 1969;161:904-6.
32. Fang YV, Cyran SJ, Albini B, Rostami R, Binder WL, Beutner EH. Relevance of complement fixing antinuclear antibodies. Int J Dermatol 1999;38:96-100.
33. Bouloc A, Joly P, Saint-Leger E, Weschsler J, Roujeau JC, Revuz J. Paraneoplastic pemphigus with circulating antibodies directed exclusively against the pemphigus vulgaris antigen desmoglein 3. J Am Acad Dermatol 2000;43:714-7.
34. Morgan BP. Complement. In: van Oss C, van Regemortel MHV, editors. Immunochemistry. New York: Marcel Dekker; 1994. p. 903-23.
35. Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol 1998;111:308-13.
36. Foedinger D, Sterniczky B, Elbe A, Anhalt G, Wolff K, Rappersberger K. Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major. J Invest Dermatol 1996;106:1012-6.
37. Foedinger D, Elbe-Burger A, Sterniczky B, Lackner M, Hotvat R, Wolff K, et al. Erythema multiforme associated human autoantibodies against desmoplakin I and II: Biochemical characterization and passive transfer studies into newborn mice. J Invest Dermatol 1998;111:503-10.
38. Taylor RN, Fulford KM; Consultants: Beutner EH, Cherry WB, Feeley JC, McKinney RM, Palmer DF. Proficiency testing: Summary Analysis; Diagnostic Immunology; Special Study - Antinuclear Antibodies. Atlanta: Centers for Disease Control, Public Health Service of Dept of Health and Human Services; 1980. p. 1-14.
39. Beutner EH, Cunningham RK, Chorzelski TP. Pathologic and physiologic autoimmunity. In: Beutner EH, Chorzelski TP, editors. Immunopathology of the Skin. 3rd Ed. New York: John Wiley & Sons; 1987. p. 153-73.
40. Beutner EH. Part II on Humeral immune responses in psoriasis. In: Autoimmunity in Psoriasis. Boca Raton (FL): CRC Press; 1982. p. 39-161.